<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383733</url>
  </required_header>
  <id_info>
    <org_study_id>NP25448</org_study_id>
    <nct_id>NCT01383733</nct_id>
  </id_info>
  <brief_title>A Study of RO5458640 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Multiple Ascending Dose (MAD) Study of RO5458640, a Humanized Monoclonal Antibody Against the TNF-like Weak Inducer of Apoptosis (TWEAK) Ligand, in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multicenter, open-label, multiple ascending dose study will evaluate the safety,&#xD;
      tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO5458640 in patients with&#xD;
      advanced solid tumors. Cohorts of patients will receive ascending doses of RO5458640&#xD;
      intravenously, either weekly or every 2 weeks or every 3 weeks, until disease progression or&#xD;
      unacceptable toxicity occurs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) according to CTEP Common Terminology Criteria for Adverse Events Version 4.0</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: area under the concentration - time curve (AUC) on two administration schedules</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response according to RECIST criteria</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antigenicity: Human anti-human antibody [HAHA] profile</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5458640</intervention_name>
    <description>Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients, &gt;/= 18 years of age&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignant solid tumors&#xD;
&#xD;
          -  Measurable and/or evaluable disease according to RECIST 1.1 criteria&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy, radiotherapy, or hormonal therapy for cancer within 3 weeks of&#xD;
             first study treatment, except for short course palliative radiotherapy for pain&#xD;
&#xD;
          -  Antibody therapy or other immunotherapy currently or less than 21 days prior to study&#xD;
             treatment&#xD;
&#xD;
          -  Current immunosuppressive therapy, including those prescribed for organ&#xD;
             transplantation and rheumatologic disease&#xD;
&#xD;
          -  Corticoid therapy &gt; 10 mg/day prednisone or equivalent&#xD;
&#xD;
          -  Patients who have not recovered from &gt; grade 1 (NCI CTCAE) prior adverse events from&#xD;
             any cancer therapy, except for alopecia&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Known hypersensitivity to any component of RO5458640 or previous severe&#xD;
             hypersensitivity reactions to monoclonal antibody therapy&#xD;
&#xD;
          -  History of active seizure disorder&#xD;
&#xD;
          -  History of CNS or leptomeningeal metastases, except for clinically stable disease for&#xD;
             at least 3 weeks prior to first study drug&#xD;
&#xD;
          -  Cardiovascular illness: CVA or MI &lt; 6 months prior to study, CHF &gt; NYHA Class 2, QTcF&#xD;
             &gt;480 msec.&#xD;
&#xD;
          -  Active infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

